- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02343718
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
A Study of Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Children's and Women's Health Centre of BC Branch
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Izaak Walton Killam (IWK) Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- CHU Sainte-Justine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have histological verification of malignancy at initial diagnosis or at relapse.
Note: Histological verification is not required for patients with optic pathway gliomas, or patients with pineal tumours and elevations of CSF or serum tumour markers
- Solid tumours (excluding soft tissue sarcomas), CNS and localized brainstem tumours (excluding diffuse intrinsic pontine gliomas (DIPG)) or,
- Lymphomas including Hodgkin's disease, non-Hodgkin's lymphoma and post-transplant lymphoproliferative disease (PTLD)
- Patients must have relapsed or refractory disease for which there is no known curative therapy, with either measurable or evaluable disease
- Age ≥ 1 year and ≤ 18 years at time of registration
Performance status:
- Patients ≤ 16 years: Lansky ≥ 50%
- Patients ≥ 16 years: Karnofsky > 50%
Prior Therapy
Patients must have received at least one prior regimen prior to registration. There is no limit to the number of prior regimens. Patients must have recovered from the acute effects and reversible toxicities related to prior therapy and have adequate washout prior to study entry as follows:
Surgery:
Previous major surgery is permitted provided that it has been at least 28 days prior to registration and wound healing has occurred. Additionally, at least 7 days must have elapsed since last biopsy or other minor surgery and wound healing must have occurred.
Radiation:
Prior radiotherapy is permitted provided that from last dose to registration:
- At least 90 days have elapsed from total body irradiation, craniospinal radiotherapy or if ≥ 50% radiation of pelvis.
- At least 6 weeks have elapsed from other substantial bone marrow irradiation.
- At least 2 weeks have elapsed from local palliative radiotherapy (small port),
- At least 8 weeks have elapsed from 131I-MIBG therapy for neuroblastoma.
Chemotherapy:
Prior myelosuppressive chemotherapy is permitted provided that it has been at least 3 weeks (6 weeks if nitrosurea) from last administration.
Prior therapy with vinblastine, mTOR inhibitors (such as temsirolimus or sirolimus) is permitted provided patients did not develop progressive disease during treatment and patients have never had to discontinue treatment due to severe adverse events such as interstitial lung disease. At least 3 weeks must have elapsed from the last administration of these agents and registration.
Other Therapy:
Patients may have received other therapies provided that an adequate time has elapsed from completion of therapy/last dose as follows:
- At least 60 days from stem cell transplant/rescue without total body irradiation and no signs of graft-versus-host disease (GVHD).
- At least 7 days (2 weeks for peg-filgrastim) from completion of therapy with hematopoietic growth factors.
- At least 3 half-lives from last administration of monoclonal antibodies.
- At least 6 weeks from any other immunotherapy (e.g. vaccines).
For biologic anti-neoplastic agents, the longer of the following must have elapsed from last administration prior to study entry: At least 2 weeks or, Standard cycle length of prior regimen or, 5 half-lives.
- Adequate Bone Marrow Function, defined as:
- Absolute neutrophil count (ANC) ≥ 1.0x10^9/L.
- Platelets ≥ 100 x 10^9/L (transfusion independent defined as not receiving platelet transfusions within 7 days prior to registration).
Hemoglobin > 80 g/L (may receive RBC transfusions). Patients with known bone marrow disease will be eligible for the study provided they meet bone marrow criteria above and they are not known to be refractory to red cell or platelet transfusions.
- Adequate Renal Function, defined as:
- Measured creatinine clearance/GFR ≥ 70 mL/min/1.73 m2 OR,
Serum creatinine ≤ 1.5 x ULN for age.
- Adequate Liver Function, defined as:
- Total bilirubin ≤ 1.5 x upper limit normal for age.
- ALT ≤ 1.5 x upper limit of normal.
Serum albumin ≥ 20 g/L.
- Adequate Metabolic Function, defined as:
- Serum triglyceride level ≤ 3.42 mmol/L (300 mg/dL).
- Serum cholesterol level ≤ 7.75 mmol/L (300 mg/dL).
- Blood glucose ≤ ULN for age. Initial sampling may be random; if abnormal, fasting blood glucose must be obtained and be within the upper normal limits for age.
Adequate Pulmonary Function, defined as:
- No dyspnea at rest.
- O2 saturations of ≥ 92% on room air.
- Patients with any baseline respiratory symptoms, or with a history of pulmonary toxicity, and who are old enough to complete pulmonary function tests, should have documented FEV1 and vital capacity ≥ 50% normal value.
- Electrolytes: ≤ grade 1 (Potassium, Calcium, Magnesium, Phosphate)
- Patient or guardian consent must be obtained on all patients according to local Institutional and/or University Human Experimentation Committee requirements. Children > 8 years old whose parent or guardian has signed consent on their behalf may also sign assent if desired
- Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating centre
- In accordance with NCIC CTG policy, protocol treatment is to begin within 5 working days of patient registration
Exclusion Criteria:
Patients with serious illness or medical condition that would not permit the patient to be managed according to the protocol including, but not limited to:
- Active or uncontrolled infections;
- Uncontrolled diabetes;
- Any other medical conditions that might be aggravated by treatment;
- History of an underlying inherited or ongoing bleeding disorder;
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events (e.g. heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age) or mean resting corrected QT interval (QTc) > 470 msec).
- Patients with a history of allergic reactions or known hypersensitivity to the study drug(s) or their components, or compounds of similar chemical or biologic composition.
- Patients with lymphoma or solid tumours (except primary CNS tumours) who have untreated brain metastases, untreated spinal cord compression or meningeal metastases are not eligible (CNS imaging is not required to rule this out unless there is a clinical suspicion of CNS disease). Patients with treated brain metastases who have radiologic evidence of stable brain metastases, with no evidence of cavitation or hemorrhage in the brain lesion, are eligible providing that they are asymptomatic. If being treated with corticosteroids, must be at a stable or decreasing dose for at least 7 days prior to study entry.
Concurrent Medications
- Patients receiving other investigational agents.
- Patients receiving other anti-cancer agents, or radiation therapy.
- Patients receiving angiotensin-converting enzyme (ACE) inhibitors.
- Patients receiving QT/QTc-prolonging drugs.
- Patients receiving anticoagulants.
- Patients receiving anti-GVHD or agents to prevent organ rejection post-transplant.
- Patients receiving strong/potent CYP3A4/5 substrates/inhibitors/inducers. These agents must have been discontinued for at least 14 days prior to registration. Grapefruit juice is also not permitted for at least 14 days prior to registration and at any time during study participation.
- Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use a highly effective contraceptive method. Pregnant or breast feeding females will not be entered on this study due to the potential fetal and teratogenic adverse events.
- Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vinblastine and Temsirolimus
Vinblastine starting dose: Weight >12 kg 4mg/m^2 Weight ≤ 12 kg 0.13mg/kg IV push for 1 minute Days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles. Temsirolimus starting dose: Weight >12 kg 15mg/m^2 Weight ≤ 12 kg 0.5 mg/kg IV for 1 hour on days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: 4 years
|
To determine the recommended phase II dose (RP2D) of the combination of vinblastine and temsirolimus (administered as a weekly intravenous dose) in children with recurrent or refractory solid tumours including central nervous system (CNS) tumours and lymphoma and to describe the associated toxicities in children
|
4 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Sylvain Baruchel, Hospital for Sick Children, Toronto ON Canada
- Study Chair: Rebecca Deyell, Children's & Women's Health Centre of BC Branch, Vancouver BC, Canada
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Lymphoma
- Recurrence
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Anti-Bacterial Agents
- Protein Kinase Inhibitors
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
- Vinblastine
- Temsirolimus
- MTOR Inhibitors
Other Study ID Numbers
- I218
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Lymphoma
-
Yazeed SawalhaWithdrawnRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular... and other conditions
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditionsUnited States
-
The Lymphoma Academic Research OrganisationActive, not recruitingRefractory Indolent Adult Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Cell LymphomaFrance
-
Narendranath EpperlaWithdrawnRecurrent Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Nodal Marginal Zone Lymphoma | Recurrent Nodal Marginal Zone Lymphoma | Recurrent Splenic Marginal Zone Lymphoma | Refractory Splenic Marginal Zone Lymphoma and other conditions
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin... and other conditionsUnited States
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
Fred Hutchinson Cancer CenterMustang BioRecruitingRecurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
The Lymphoma Academic Research OrganisationLymphoma Study AssociationNot yet recruitingRefractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell LymphomaFrance
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRecurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditionsUnited States
Clinical Trials on Temsirolimus
-
Sheba Medical CenterStanley Medical Research InstituteUnknownSchizophrenia | Schizoaffective DisorderIsrael
-
St. Joseph's Healthcare HamiltonPfizer; McMaster UniversityCompletedRenal Cell CarcinomaCanada
-
AVEO Pharmaceuticals, Inc.Completed
-
Children's Hospital Medical Center, CincinnatiWithdrawnLymphoma, B-Cell | Leukemia, B-cellUnited States
-
Dana-Farber Cancer InstituteWyeth is now a wholly owned subsidiary of Pfizer; Millennium Pharmaceuticals...CompletedMultiple MyelomaUnited States
-
Mathias Witzens-HarigCharite University, Berlin, Germany; Ludwig-Maximilians - University of Munich and other collaboratorsUnknownDiffuse Large B-Cell LymphomaGermany
-
Georgetown UniversityWyeth is now a wholly owned subsidiary of PfizerCompletedAdvanced Solid TumorsUnited States
-
Goethe UniversityCompletedAcute Myeloblastic LeukemiaGermany
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedBreast Neoplasms
-
Loyola UniversityWyeth is now a wholly owned subsidiary of PfizerTerminated